HS-10241 |
HS-10241 |
Phase 3 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Solid tumours; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Zanzalintinib |
XL-092 |
Phase 3 Clinical |
Exelixis Inc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
Recombinant plasmid-hepatocyte growth factor |
Pudk-HGF |
Phase 3 Clinical |
Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd, Academy Of Military Medical Sciences |
Ischemia; Peripheral Arterial Disease |
Details
|
Refanalin |
ANG-3777; BB-3; SNV-003 |
Phase 3 Clinical |
Vifor Pharma Ag, Elicio Therapeutics |
Myocardial Infarction; Pneumonia; Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Delayed Graft Function |
Details
|
Fosgonimeton |
ATH-1017; NDX-1017 |
Phase 3 Clinical |
M3 Biotechnology |
Alzheimer Disease; Lewy Body Disease |
Details
|
Sitravatinib |
MG-91516; MGCD-516; IND-155305; MG-516 |
Phase 3 Clinical |
Mirati Therapeutics Inc |
Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Mouth Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Ureteral Neoplasms; Hepatic Insufficiency; Solid tumours; Liposarcoma; Uveal melanoma; Lung Diseases; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Kidney Neoplasms |
Details
|
SC-0011 |
SC-0011 |
Phase 3 Clinical |
Shijiazhuang Zhikang Hongren New Drug Development Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Telisotuzumab vedotin |
ABT-399; ABBV-399 |
Phase 3 Clinical |
Abbvie Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
AL-2846 |
AL-2846 |
Phase 3 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Advenchen Laboratories Nanjing Ltd |
Neoplasms; Carcinoma, Non-Small-Cell Lung; Neurofibromatosis 1; Neurilemmoma; Lung Neoplasms; Thyroid Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Solid tumours; Ganglioglioma; Neurofibroma; Neurofibromatoses; Pancreatic Neoplasms; Stomach Neoplasms; Bone metastases; Ovarian Neoplasms; Liver Neoplasms |
Details
|
Ningetinib Tosylate |
CT-053-PTSA; CT-053 |
Phase 2 Clinical |
Hec Pharm Co Ltd |
Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Pamvatamig |
MCLA-129 |
Phase 2 Clinical |
Merus Nv |
Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Merestinib |
5OGS5K699E; LY-2801653 |
Phase 2 Clinical |
Eli Lilly And Company |
Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
Sym-015 |
Sym-015 |
Phase 2 Clinical |
Symphogen A/S |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
ABN-401 |
ABN-401; KDDF-201603-08 |
Phase 2 Clinical |
Abion Inc |
Solid tumours; Neoplasms |
Details
|
REGN-5093-M114 |
METxMET-M114; REGN5093-M114 |
Phase 2 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
Glesatinib |
MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 |
Phase 2 Clinical |
Mirati Therapeutics Inc |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bafisontamab |
FIT-013a; EMB-01 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Biliary Tract Neoplasms; Liver Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
GB-263 |
GB-263; GB-263T |
Phase 2 Clinical |
Genor Biopharma Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Elzovantinib |
TPX-0022 |
Phase 2 Clinical |
Turning Point Therapeutics Inc |
Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
Do-1 |
Do-1 |
Phase 2 Clinical |
DeuterOncology NV |
Lung Neoplasms |
Details
|
EMI-137 |
EMI-137; GE-137 |
Phase 2 Clinical |
Ge Healthcare |
Esophageal Neoplasms; Colonic Neoplasms; Extranodal Extension; Barrett Esophagus |
Details
|
Davutamig |
REGN-5093 |
Phase 2 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
CKD-702 |
|
Phase 2 Clinical |
Chong Kun Dang Pharmaceutical Corp |
Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant adenovirus-hepatocyte growth factor(Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences) |
|
Phase 2 Clinical |
Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences, Beijing Haitai United Pharmaceutical Technology Development Co Ltd |
Myocardial Ischemia |
Details
|
RC-108 |
RC-108; RC108 |
Phase 2 Clinical |
RemeGen Co Ltd |
Solid tumours; Digestive System Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Emibetuzumab |
LA-480; LY-2875358 |
Phase 2 Clinical |
Eli Lilly And Company |
Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
SHR-A1403 |
SHR-A1403 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Solid tumours |
Details
|
CM-118 |
CM-118 |
Phase 1 Clinical |
Xcovery |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Kanitinib |
CX-1003 |
Phase 1 Clinical |
Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd |
Solid tumours |
Details
|
BPI-9016 |
BPI-9016; BPI-9016M |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
HLX-55 |
HLX-55; KTN-0216 |
Phase 1 Clinical |
Kolltan Pharmaceuticals Inc |
Solid tumours |
Details
|
Pamufetinib |
TAS-115 |
Phase 1 Clinical |
Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Boxitinib Hydrochloride |
|
Phase 1 Clinical |
Hec Pharm Co Ltd |
Stomach Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Glioma; Lung Neoplasms |
Details
|
BYON-3521 |
BYON-3521 |
Phase 1 Clinical |
Byondis Bv |
Solid tumours; Neoplasms |
Details
|
ATH-1020 |
ATH-1020 |
Phase 1 Clinical |
Athira Pharma Inc |
|
Details
|
QBH-196 |
QBH-196 |
Phase 1 Clinical |
Shenyang Pharmaceutical University |
Solid tumours; Stomach Neoplasms |
Details
|
[11C]savolitinib |
[11C]savolitinib |
Phase 1 Clinical |
Astrazeneca Plc |
|
Details
|
[14C]HS-10241 |
[14C]HS-10241 |
Phase 1 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
FPI-2107 |
[111In]-FPI-2107 |
Phase 1 Clinical |
|
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
FPI-2053 |
FPI-2053 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
ANS-014004 |
ANS014004; ANS-014004; ANS-01; ANS01 |
Phase 1 Clinical |
Beijing Avistone Pharmaceuticals Biotechnology Co Ltd |
Solid tumours; Neoplasms |
Details
|
FPI-2068 |
[225Ac]-FPI-2068; FPI-2068 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
SPH-3348 |
SPH-3348; SPH3348; I-020 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Solid tumours; Neoplasms |
Details
|
HS-20117 |
HS-20117; PM1080; PM-1080 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
MYTX-011 |
MYTX-011 |
Phase 1 Clinical |
Mythic Therapeutics Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
AZD9592 |
AZD-9592; AZD9592 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
TAVO-412 |
TAVO-412 |
Phase 1 Clinical |
Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd |
Solid tumours; Neoplasms |
Details
|
ABBV-400 |
ABBV-400 |
Phase 1 Clinical |
Abbvie Inc |
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
NP-107 |
NP107; NP-107 |
Phase 1 Clinical |
Shanghai Nawei Biotechnology Co Ltd |
Solid tumours |
Details
|
ASKC-202 |
ASKC202 |
Phase 1 Clinical |
Jiangsu Aosaikang Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
LMV-12(HE003) |
LMV-12(HE003) |
Phase 1 Clinical |
Nanchang Hongyi Technology Co Ltd |
Solid tumours |
Details
|
GST-HG161 |
GST-HG161 |
Phase 1 Clinical |
Wuxi Apptec Co Ltd, Fujian Cosunter Pharmaceutical Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Hepatocellular |
Details
|
Metatinib Trometamol |
BMS-817378; SIM-817378 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms |
Details
|
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) |
NP-01 |
Phase 1 Clinical |
Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms |
Details
|
SAIT-301 |
SAIT-301 |
Phase 1 Clinical |
Samsung Medical Center |
Neoplasms |
Details
|
NPS-1034 |
HOPE-777; KDDF-201111-02 |
|
Neopharma Ltd |
|
Details
|
CGT-1403 |
CGT-1403 |
|
Cgenetech(Suzhou China) Co Ltd |
Neoplasms |
Details
|
HS-10241 |
HS-10241 |
Phase 3 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Solid tumours; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Zanzalintinib |
XL-092 |
Phase 3 Clinical |
Exelixis Inc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
Recombinant plasmid-hepatocyte growth factor |
Pudk-HGF |
Phase 3 Clinical |
Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd, Academy Of Military Medical Sciences |
Ischemia; Peripheral Arterial Disease |
Details
|
Refanalin |
ANG-3777; BB-3; SNV-003 |
Phase 3 Clinical |
Vifor Pharma Ag, Elicio Therapeutics |
Myocardial Infarction; Pneumonia; Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Delayed Graft Function |
Details
|
Fosgonimeton |
ATH-1017; NDX-1017 |
Phase 3 Clinical |
M3 Biotechnology |
Alzheimer Disease; Lewy Body Disease |
Details
|
Sitravatinib |
MG-91516; MGCD-516; IND-155305; MG-516 |
Phase 3 Clinical |
Mirati Therapeutics Inc |
Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Mouth Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Ureteral Neoplasms; Hepatic Insufficiency; Solid tumours; Liposarcoma; Uveal melanoma; Lung Diseases; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Kidney Neoplasms |
Details
|
SC-0011 |
SC-0011 |
Phase 3 Clinical |
Shijiazhuang Zhikang Hongren New Drug Development Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Telisotuzumab vedotin |
ABT-399; ABBV-399 |
Phase 3 Clinical |
Abbvie Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
AL-2846 |
AL-2846 |
Phase 3 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Advenchen Laboratories Nanjing Ltd |
Neoplasms; Carcinoma, Non-Small-Cell Lung; Neurofibromatosis 1; Neurilemmoma; Lung Neoplasms; Thyroid Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Solid tumours; Ganglioglioma; Neurofibroma; Neurofibromatoses; Pancreatic Neoplasms; Stomach Neoplasms; Bone metastases; Ovarian Neoplasms; Liver Neoplasms |
Details
|
Ningetinib Tosylate |
CT-053-PTSA; CT-053 |
Phase 2 Clinical |
Hec Pharm Co Ltd |
Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Pamvatamig |
MCLA-129 |
Phase 2 Clinical |
Merus Nv |
Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Merestinib |
5OGS5K699E; LY-2801653 |
Phase 2 Clinical |
Eli Lilly And Company |
Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
Sym-015 |
Sym-015 |
Phase 2 Clinical |
Symphogen A/S |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
ABN-401 |
ABN-401; KDDF-201603-08 |
Phase 2 Clinical |
Abion Inc |
Solid tumours; Neoplasms |
Details
|
REGN-5093-M114 |
METxMET-M114; REGN5093-M114 |
Phase 2 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
Glesatinib |
MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 |
Phase 2 Clinical |
Mirati Therapeutics Inc |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bafisontamab |
FIT-013a; EMB-01 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Biliary Tract Neoplasms; Liver Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
GB-263 |
GB-263; GB-263T |
Phase 2 Clinical |
Genor Biopharma Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Elzovantinib |
TPX-0022 |
Phase 2 Clinical |
Turning Point Therapeutics Inc |
Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
Do-1 |
Do-1 |
Phase 2 Clinical |
DeuterOncology NV |
Lung Neoplasms |
Details
|
EMI-137 |
EMI-137; GE-137 |
Phase 2 Clinical |
Ge Healthcare |
Esophageal Neoplasms; Colonic Neoplasms; Extranodal Extension; Barrett Esophagus |
Details
|
Davutamig |
REGN-5093 |
Phase 2 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
CKD-702 |
|
Phase 2 Clinical |
Chong Kun Dang Pharmaceutical Corp |
Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant adenovirus-hepatocyte growth factor(Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences) |
|
Phase 2 Clinical |
Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences, Beijing Haitai United Pharmaceutical Technology Development Co Ltd |
Myocardial Ischemia |
Details
|
RC-108 |
RC-108; RC108 |
Phase 2 Clinical |
RemeGen Co Ltd |
Solid tumours; Digestive System Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Emibetuzumab |
LA-480; LY-2875358 |
Phase 2 Clinical |
Eli Lilly And Company |
Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
SHR-A1403 |
SHR-A1403 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Solid tumours |
Details
|
CM-118 |
CM-118 |
Phase 1 Clinical |
Xcovery |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Kanitinib |
CX-1003 |
Phase 1 Clinical |
Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd |
Solid tumours |
Details
|
BPI-9016 |
BPI-9016; BPI-9016M |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
HLX-55 |
HLX-55; KTN-0216 |
Phase 1 Clinical |
Kolltan Pharmaceuticals Inc |
Solid tumours |
Details
|
Pamufetinib |
TAS-115 |
Phase 1 Clinical |
Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Boxitinib Hydrochloride |
|
Phase 1 Clinical |
Hec Pharm Co Ltd |
Stomach Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Glioma; Lung Neoplasms |
Details
|
BYON-3521 |
BYON-3521 |
Phase 1 Clinical |
Byondis Bv |
Solid tumours; Neoplasms |
Details
|
ATH-1020 |
ATH-1020 |
Phase 1 Clinical |
Athira Pharma Inc |
|
Details
|
QBH-196 |
QBH-196 |
Phase 1 Clinical |
Shenyang Pharmaceutical University |
Solid tumours; Stomach Neoplasms |
Details
|
[11C]savolitinib |
[11C]savolitinib |
Phase 1 Clinical |
Astrazeneca Plc |
|
Details
|
[14C]HS-10241 |
[14C]HS-10241 |
Phase 1 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
FPI-2107 |
[111In]-FPI-2107 |
Phase 1 Clinical |
|
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
FPI-2053 |
FPI-2053 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
ANS-014004 |
ANS014004; ANS-014004; ANS-01; ANS01 |
Phase 1 Clinical |
Beijing Avistone Pharmaceuticals Biotechnology Co Ltd |
Solid tumours; Neoplasms |
Details
|
FPI-2068 |
[225Ac]-FPI-2068; FPI-2068 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
SPH-3348 |
SPH-3348; SPH3348; I-020 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Solid tumours; Neoplasms |
Details
|
HS-20117 |
HS-20117; PM1080; PM-1080 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
MYTX-011 |
MYTX-011 |
Phase 1 Clinical |
Mythic Therapeutics Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
AZD9592 |
AZD-9592; AZD9592 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
TAVO-412 |
TAVO-412 |
Phase 1 Clinical |
Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd |
Solid tumours; Neoplasms |
Details
|
ABBV-400 |
ABBV-400 |
Phase 1 Clinical |
Abbvie Inc |
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
NP-107 |
NP107; NP-107 |
Phase 1 Clinical |
Shanghai Nawei Biotechnology Co Ltd |
Solid tumours |
Details
|
ASKC-202 |
ASKC202 |
Phase 1 Clinical |
Jiangsu Aosaikang Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
LMV-12(HE003) |
LMV-12(HE003) |
Phase 1 Clinical |
Nanchang Hongyi Technology Co Ltd |
Solid tumours |
Details
|
GST-HG161 |
GST-HG161 |
Phase 1 Clinical |
Wuxi Apptec Co Ltd, Fujian Cosunter Pharmaceutical Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Hepatocellular |
Details
|
Metatinib Trometamol |
BMS-817378; SIM-817378 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms |
Details
|
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) |
NP-01 |
Phase 1 Clinical |
Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms |
Details
|
SAIT-301 |
SAIT-301 |
Phase 1 Clinical |
Samsung Medical Center |
Neoplasms |
Details
|
NPS-1034 |
HOPE-777; KDDF-201111-02 |
|
Neopharma Ltd |
|
Details
|
CGT-1403 |
CGT-1403 |
|
Cgenetech(Suzhou China) Co Ltd |
Neoplasms |
Details
|